Press Releases for the Psychedelics Industry

Psychedelics News

Press Releases

30 May 2024

PurMinds NeuroPharma Announces PUR501 as Lead Candidate Novel Non-Hallucinogenic Neuroplastogen

PurMinds NeuroPharma to initiate preclinical development of lead candidate PUR501 in 2024 in preparation for IND submission....

By Madison Roberts

Press Releases

24 May 2024

8 Above and award-winning filmmaker Jon Reiss announce the launch of the groundbreaking podcast Plantscendence

8 Above and award-winning filmmaker and author Jon Reiss announced the launch of the groundbreaking podcast Plantscendence. Join Reiss on a transformative journey as he explores the world of psychedelics...

By Microdose

Breaking News, Press Releases

13 May 2024

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

AbbVie and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research...

By Madison Roberts

Press Releases

8 May 2024

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Enveric Biosciences announced that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company to exclusively out-license two patent families of Methods for Treating Breast...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

6 May 2024

Lykos Therapeutics Announces FDA Advisory Committee Meeting to Review Investigational MDMA-Assisted Therapy for PTSD

The U.S. Food and Drug Administration's ("FDA") Psychopharmacologic Drugs Advisory Committee ("PDAC") will review data supporting the new drug application ("NDA") for midomafetamine (MDMA) capsules used in combination with psychological...

By Madison Roberts

Press Releases

2 May 2024

Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the close of a $103 million Series A financing co-led by MPM BioImpact and...

By Madison Roberts

Industry, Press Releases

5 Dec 2022

MY Self Ketamine Clinic Launches Ketamine Access Nonprofit

MY Self Wellness Ketamine Clinic Launches Nonprofit Organization Warriors of Consciousness, Helping Those Who Cannot Afford Psychedelic Ketamine Therapy Treatments...

By Microdose

Press Releases

21 Nov 2022

Nushama & Awakn Sign Agreement for Alcohol Disorder Treatment in NYC

NUSHAMA AND AWAKN BRING REVOLUTIONARY ALCOHOL USE DISORDER TREATMENT TO NEW YORK — EFFICACY AT A FRACTION OF THE USUAL COST...

By Microdose NewsDesk

Industry, Press Releases

14 Sep 2022

Microdose Psychedelic Insights Partners with Concordia Annual Summit

Microdose is proud to announce its official partnership with the Concordia Annual Summit, presenting the first-ever Mental Health & Psychedelics Panel....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result